Preclinical and translational pharmacokinetic (PK) modeling of the self-assembling and disassembling (SADA) bispecific fusion protein CD38-SADA for first-in-human …
用户v5qcNFE25_BU
24天前
45
10
已关闭
DOI:
文献链接:
其他信息:
BH Santich, CA Russell, LL Wang, M Düring…
Cancer …, 2025
aacrjournals.org
Background: PRIT is designed to deliver tumor-targeted radiation while limiting exposure to healthy tissues. CD38-SADA binds CD38 and select radioisotopes chelated to tetraxetan (DOTA) and contains a p53-derived domain mediating the self-assembly of tetramers from monomers in a reversible, concentration-dependent manner. Preclinical studies have demonstrated dose-dependent anti-tumor efficacy of two-step CD38-SADA PRIT with 177Lu-DOTA administered 48h after an initial CD38-SADA infusion. Here, we report preclinical PK …
